Press Releases Ypsomed Group

Burgdorf – In the business year 2015/16, the Ypsomed Group generated consolidated sales totaling CHF 336.9 million (prior year: CHF 306.6 million). Compared with the previous year, this represents an increase in sales of 9.9%. The operating results (EBIT) also increased by 55.7% compared to the previous year, from CHF 28.5 million to CHF 44.4 million and lies considerably above the expectations of CHF 41 million. As a result, the profitability at the EBIT level lies at 13.2% (prior year: 9.3%) – despite the present currency exchange situation. For the current business year 2016/17, Ypsomed expects an accelerated growth in sales of around 12% and an EBIT of approximately CHF 55 million.

Press Releases Ypsomed Group

Burgdorf – From March 2016 the Ypsomed Group will be gradually introducing the tubing free insulin patch pump mylife OmniPod for distribution via existing Group companies also in France, Finland, Denmark, Ireland and Luxembourg. In so doing Ypsomed is taking a considerable step towards expanding the growth basis of its diabetes supply business.

Burgdorf – The reusable and affordable YpsoPen is becoming more and more popular. In the coming weeks, it will be supplied to Ukraine. The pharma company Indar, a private joint-stock company (PrJSC), is launching the insulin pen developed in Switzerland.

Press Releases Ypsomed Group

Burgdorf – Dongbao has been appointed the exclusive distributor for Ypsomed's mylife Clickfine pen needles in China.

Press Releases Ypsomed Group

Burgdorf – A significant part of this extension is yet another major project for long-standing partner Sanofi.